New Accelerated Regulatory Paths in China

Lei Liu


VP of Regulatory Affairs of FMD

At the end of August, China’s legislature finally approved the long-awaited Drug Administration Law.
Capping the dizzying regulatory reform since 2015, the new law codifies many of the popular provisions,
such as the 60-day IND default approval.